

A dedicated European multi-stakeholder framework for PM - The International Consortium for Personalised Medicine -

Monika Frenzel, Agence National de la Recherche, CSA ICPerMed Secretariat

EU-Africa PerMed 1st Stakeholder Workshop, 9-10 February 2022



ICPerMed – An International Consortium

- Almost 50 European and international partners
- Members include public and private `not-for-profit` health research funding and policy organisations and the European Commission



ICPerMed pools
competences and
expertise on a high
policy level

Personalised Medicine (PM) – A definition

*PM [] “refers to a medical model using
 Characterisation of individuals’ phenotypes and genotypes
 (e.g. **molecular profiling, medical imaging, lifestyle data**)
 for tailoring the right **therapeutic** strategy for the right
 person at the right time,
 and/or to determine the **predisposition** to disease
 and/or to deliver timely and targeted **prevention**”.*


According to: Horizon 2020 and
 European Council Conclusions on personalised medicine for patients (2015/C 421/03)

Personalised Medicine: A major opportunity for society to provide benefits to patients and citizens and health systems

Key questions that Personalised Medicine (PM) tackles are:

- Why does a treatment for a certain disease work very well for one patient, but poorly or not at all for another patient?
- What is the benefit of individual molecular, clinical or lifestyle data for the development of personalised prevention, diagnostics, and treatment?
- How can the knowledge of an individual genetic profile or personal setting help to avoid health risks and support a healthy life?
- Can the use of PM be cost effective?

Only together we can bring Personalised Medicine to the next level and towards implementation



Overall aim:

To coordinate and promote research along the full value chain to develop and evaluate personalised medicine approaches

Overall focus on full value chain as outlined in the Action Plan



Working groups (WG) for the next three years:

- Clinical Studies in PM
- PM in healthcare
- Patient empowerment
- Education & Curricula in PM
- Health economic value of PM



WG-Members: ICPerMed members & selected external experts

Aim: Implementing the ICPerMed activities prioritised by the Executive Committee

- Collect and present best-practice examples
- Develop recommendations and guidelines
- Develop and contribute to white papers of ICPerMed


Bringing together stakeholders to advance personalised medicine

Advisory Board

Stakeholder Forum



Acting on global scale



Strategic papers


- 1) ICPerMed Recognition
- 2)

Creating synergies through conferences and workshops



https://www.icpermed.eu/en/best_practice_examples.php

Increasing commitment for and investment in PM



Since FP7 and during Horizon 2020, the EC provided a budget of more than 2 billion Euros into PM.

- Increased efforts in the PM field for PM research and implementation on regional and national level but also in collaborations across countries
- EC supporting joint efforts and activities related to PM to establishing Europe as a global leader in the field but also to foster cross boarder/international collaboration

International collaboration: Key to foster the uptake of personalised approaches in healthcare

- Excellent experts and initiatives located around the globe
- Reaching critical mass of data from various sources to develop and train algorithms and models used in PM approaches
 - ensuring that developed approaches are applicable as broadly as possible and not limited to a specific regional context → increase the value of developments for the common good.
- Common understanding of personalised medicine
- Promotion of international standards and global collaborations
- Make healthcare more efficient and equitable

ICPerMed Family: Europe and collaboration with Africa



- Dedicated project focusing on collaboration between Africa and Europe.



- As ministry or funding organisation: Become a member or observer of ICPerMed
- As other type of organisation: Join the stakeholder group
- Participate in the ICPerMed recognition open worldwide
 → Example: Winner in 2020: Maritha Kotze (Department of Pathology, Stellenbosch University and National Health Laboratory Service, Tygerberg Hospital, South Africa)



- Participation in ICPerMed Family activities
 → Example: Joint research funding in personalised medicine: Participation of the SAMRC in the Joint Transnational Call for proposals of ERA PerMed 2022

ICPerMed Recognition 2021

ICPerMed “Best Practice in Personalised Medicine” Recognition

Objective: honour, encourage, promote and disseminate outstanding evidence-based applications in the field of personalised medicine, focusing on the implementation of personalised medicine research.

- ✓ Winners present their approaches on the ICPerMed website and during the next ICPerMed Event.
- ✓ 500 € non-cash value support for dissemination

**The deadline for proposal submission is extended until
18 February 2022 <https://www.icpermed.eu/en/887.php>**

Upcoming events

ICPerMed conference – October 2022

Working title:

« Personalised Medicine - Opportunities and Incentives »

More news available soon!

More information about ICPerMed

Mail: ICPerMed@dlr.de

Internet: www.icpermed.eu



@ICPerMed



ICPerMed - The International Consortium
for Personalised Medicine

<https://www.icpermed.eu/en/services-newsletter.php>

ICPerMed@agencerecherche.fr